Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families. The Company is focused on developing, manufacturing and commercializing specialty CNS pharmaceuticals for our own pipeline. Corium's lead product, CorplexTM Donepezil, is a once-weekly transdermal patch containing the active ingredient in Aricept for the treatment of patients with mild, moderate and severe Alzheimer’s disease. The Company's transdermal technologies enable the development of innovative new products through the simple, safe and efficient delivery of both small and large molecule therapeutics, which provides significant clinical and commercial advantages, including valuable product lifecycle management.

TypePublic
HQMenlo Park, US
Founded1999
Size (employees)213 (est)
Websitecoriumintl.com
Corium International was founded in 1999 and is headquartered in Menlo Park, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Corium International

Peter Staple

Peter Staple

President and Chief Executive Officer
Christina Dickerson

Christina Dickerson

Vice President of Corporate Development
Show more

Corium International Office Locations

Corium International has offices in Menlo Park and Kentwood
Menlo Park, (HQ)
235 Constitution Dr
Kentwood,
4558 50th St SE
Show all (2)
Report incorrect company information

Corium International Financials and Metrics

Corium International Revenue

Corium International's revenue was reported to be $31.86 m in FY, 2017
USD

Revenue (Q3, 2018)

7.7m

EBIT (Q3, 2018)

(10.0m)

Market capitalization (26-Nov-2018)

463.0m

Closing stock price (26-Nov-2018)

12.7

Cash (30-Jun-2018)

82.5m

EV

380.9m
Corium International's current market capitalization is $463 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

40.9m33.0m31.9m

General and administrative expense

11.2m11.6m13.2m

R&D expense

16.5m21.7m31.9m

Operating expense total

61.9m61.9m71.6m
Quarterly
USDQ2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

10.7m10.2m10.6m7.5m7.0m10.6m7.0m7.3m8.1m9.3m10.1m7.7m

General and administrative expense

1.2m3.5m2.8m3.0m3.0m3.1m3.0m3.0m3.3m3.3m4.1m3.3m

R&D expense

1.3m1.6m3.5m4.5m5.6m5.5m6.0m7.5m9.1m10.2m12.0m8.3m

Operating expense total

11.5m13.6m14.6m15.0m15.5m16.2m15.4m16.4m19.5m20.6m23.6m17.7m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

36.4m72.2m39.8m57.5m

Accounts Receivable

4.2m4.5m4.3m4.6m

Inventories

1.3m1.4m2.4m2.3m

Current Assets

45.8m81.8m48.3m65.6m
Quarterly
USDQ2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

5.3m44.2m29.5m63.0m54.4m47.4m33.1m40.6m66.6m45.2m94.2m82.5m

Accounts Receivable

4.3m4.5m4.6m3.1m3.5m4.1m2.2m3.4m4.6m4.9m4.2m3.6m

Inventories

3.0m3.1m3.3m2.9m3.2m2.8m1.9m2.7m2.5m2.5m2.0m1.7m

Current Assets

17.4m55.0m40.2m71.0m62.9m56.3m39.2m47.7m75.1m54.3m101.1m88.9m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Inventories

(255.0k)(75.0k)478.0k124.0k

Accounts Payable

700.0k1.4m(1.2m)1.4m

Cash From Operating Activities

(11.4m)(20.7m)(29.1m)(37.2m)

Purchases of PP&E

(3.2m)(973.0k)(1.4m)(2.3m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Depreciation and Amortization

141.0k159.0k162.0k168.0k177.0k178.0k

Inventories

1.9m2.7m

Accounts Payable

1.8m2.6m3.4m2.6m3.6m2.7m3.4m3.1m3.8m3.7m5.4m
USDY, 2018

EV/EBIT

-38.1 x

Financial Leverage

4.5 x
Show all financial metrics

Corium International Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Gurnet Point Capital LimitedOctober 11, 2018$504 m
Report incorrect company information

Corium International News and Updates

Global Sustained Release Excipients Market 2018-2026 Featuring Key Companies - Coating Place, Depomed, Corium International, Capsugel, Aradigm, Orbis Biosciences & Alkermes

DUBLIN, Oct. 30, 2018 /PRNewswire/ -- The "Sustained Release Excipients Market Size, Share & Trends Analysis Report By Product (Polymers, Gelatin), By Route of Administration (Oral, Transdermal), By Technology (Targeted Delivery), And Segment Forecasts, 2018 - 2026" report has been added...

RM LAW Announces Investigation of Corium International, Inc.

BERWYN, Pa., Oct. 15, 2018 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of Corium International, Inc. ("Corium" or the "Company") (NASDAQ: CORI) concerning possible breaches of fiduciary duty and other violations of law related to the...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Corium International, Inc. - CORI

NEW YORK, Oct. 12, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Corium International, Inc. ("Corium" or the "Company") (NasdaqGM:...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Corium International, Inc.

NEW YORK, Oct. 12, 2018 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Corium International, Inc. (NASDAQ: CORI) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Gurnet Point Capital. Stockholders will ...
Report incorrect company information

Corium International Blogs

Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares

Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares joshua.kelly@n… Thu, 10/11/2018 - 16:06 Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares October 11, 2018 at 4:03 PM EDT This release i…

Corium to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

MENLO PARK, Calif. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple , Corium’s President and

Corium to Report Third Quarter Fiscal 2018 Financial Results on Thursday, August 9, 2018

Corium to Report Third Quarter Fiscal 2018 Financial Results on Thursday, August 9, 2018 Content Import Thu, 08/02/2018 - 07:32 Corium to Report Third Quarter Fiscal 2018 Financial Results on Thursday, August 9, 2018 August 2, 2018 at 7:30 AM EDT This release …

Corium International Company Life and Culture

Report incorrect company information

Corium International Frequently Asked Questions

  • When was Corium International founded?

    Corium International was founded in 1999.

  • Who are Corium International key executives?

    Corium International's key executives are Peter Staple and Christina Dickerson.

  • How many employees does Corium International have?

    Corium International has 213 employees.

  • What is Corium International revenue?

    Latest Corium International annual revenue is $31.9 m.

  • What is Corium International revenue per employee?

    Latest Corium International revenue per employee is $149.6 k.

  • Who are Corium International competitors?

    Competitors of Corium International include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is Corium International headquarters?

    Corium International headquarters is located at 235 Constitution Dr, Menlo Park.

  • Where are Corium International offices?

    Corium International has offices in Menlo Park and Kentwood.

  • How many offices does Corium International have?

    Corium International has 2 offices.